{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335212","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2026-08-05T20:22:06+00:00","discovered_at":"2026-08-05T20:23:01.938212+00:00","generated_at":"2026-08-05T20:23:09.494727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytek Biosciences Q2 2026 revenue $48.1M (+6% YoY); net loss widens to $12.2M from $5.6M","bullets":["Total revenue $48.1M, up 6% YoY; GAAP gross margin improved to 59% from 52%.","Net loss $12.2M vs $5.6M loss YoY; adjusted EBITDA loss $1.5M vs positive $1.3M.","Operating expenses rose 15% to $39.7M, driven by litigation, severance, and personnel costs.","Full-year 2026 revenue guidance raised to $207M-$212M, midpoint up $1M.","Launched Cytek Borealis 7-laser, 60-color cytometer; installed base reached 3,933 units."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335212","json":"https://secwatch.observer/filing/0001193125-26-335212.json","markdown":"https://secwatch.observer/filing/0001193125-26-335212.md","text":"https://secwatch.observer/filing/0001193125-26-335212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/0001193125-26-335212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/d118986d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:23:09.494727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}